Back

γ-aminobutyric acid receptor B signaling drives glioblastoma in females in an immune-dependent manner

Pathak, A.; Palasalava, S.; Knott, M. V.; Colon, B.; Ciervo, E.; Zhou, Y.; Mitchell, J.; Pumar, O. T.; Wong, H. K. A.; Zhang, L.; Susic, N.; Shah, K. H.; Kay, K.; Chin, D.; Johnson, S.; Cheng, F.; Lyssiotis, C. A.; Watson, D. C.; Ceccarelli, M.; Shah, A.; Wahl, D.; Lathia, J.; Bayik, D.

2024-07-22 cancer biology
10.1101/2024.07.18.603996 bioRxiv
Show abstract

Sex differences in immune responses impact cancer outcomes and treatment response, including in glioblastoma (GBM). However, host factors underlying sex specific immune-cancer interactions are poorly understood. Here, we identify the neurotransmitter {gamma}-aminobutyric acid (GABA) as a driver of GBM-promoting immune response in females. We demonstrated that GABA receptor B (GABBR) signaling enhances L-Arginine metabolism and nitric oxide synthase 2 (NOS2) expression in female granulocytic myeloid-derived suppressor cells (gMDSCs). GABBR agonist and GABA analog promoted GBM growth in females in an immune-dependent manner, while GABBR inhibition reduces gMDSC NOS2 production and extends survival only in females. Furthermore, female GBM patients have enriched GABA transcriptional signatures compared to males, and the use of GABA analogs in GBM patients is associated with worse short-term outcomes only in females. Collectively, these results highlight that GABA modulates anti-tumor immune response in a sex-specific manner, supporting future assessment of GABA pathway inhibitors as part of immunotherapy approaches.

Published in Nature Cancer (predicted rank #3) · training set

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.